Biocon falls 1% after FDA raises 5 Bengaluru facility issues
Business
Biocon's stock slipped 1% on Thursday, April 30, 2026 after the US Food and Drug Administration raised five issues at its Bengaluru biosimilars facility during a recent inspection.
The company says these are just procedural points and insists there's no risk to data integrity or quality oversight.
Biocon wins Health Canada denosumab approvals
Biocon plans to quickly address the US Food and Drug Administration's concerns with a corrective action plan.
Despite this bump, the company recently scored Health Canada approval for two denosumab biosimilars, Bosaya and Vevzuo, for osteoporosis and cancer-related bone conditions, showing it's still making progress in the global biosimilars market.